An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

Abstract

We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400mg PO given once daily is safe and effective for the treatment of community-acquired pneumonia. The drug had a favorable safety profile and a good clinical and bacteriological efficacy.

Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

“…In this study, the frequency of gatifloxacin-induced adverse events was 15.7% and the majority of adverse events including nausea, headache, diarrhoea and dizziness were mild or moderate in severity, except for one patient who had treatment-related gastric soreness. This study demonstrates a safety profile of gatifloxacin similar to that of previous reports [27][28][29][30].…”

Neumonía aguda adquirida en la comunidad en adultos: Actualización de los lineamientos para el tratamiento antimicrobiano inicial basado en la evidencia local del Grupo de Trabajo de Sudamérica (ConsenSur II)

“…En la mayoría de la regiones, S. pneumoniae corresponde aproximadamente a los dos tercios de los casos de NAC en los cuales se efectúa un diagnóstico del agente etiológico [5][6][7][8][9][10]15,16,52,[54][55][56][57][58]210 . Además, H. infl uenzae y, en menor grado, Moraxella catarrhalis, como así también bacterias atípicas, están apareciendo como frecuentes agentes causales en varios pacientes de ciertas regiones 1,9,14,15,52,60,210 y pueden observarse eventuales diferencias en la incidencia de M. pneumoniae relacionada con la presencia o ausencia de epidemia al momento del estudio 9 .…”

“…Sin embargo, para el grupo 2a, el panel de consenso prefi ere la combinación de aminopenicilina/inhibidor de β-lactamasa como la opción primaria a ceftriaxona, debido a la potencial variedad y contagio de bacterias gramnegativas con múltiple resistencia a este último fármaco en el ambiente hospitalario 158 . De hecho, la prevalencia de estos microorganismos, especialmente aquellos que producen un amplio espectro de β-lactamasas, es extremadamente alto en América Latina 57,[159][160][161][162] . En un hospital de Argentina, el uso de amoxicilina/sulbactam o ampicilina/sulbactam para el tratamiento de pacientes con NAC internados en sala general, aumentó de 21% en 1999 a 78% en al año 2001, mientras que el uso de oximino-cefalosporinas de uso parenteral disminuyó de 47 a 6%.…”

Changing epidemiology of melioidosis? A case of acute pulmonary melioidosis with fatal outcome imported from Brazil

“…The diagnosis of melioidosis was not suspected in our patient since he had not travelled to a known endemic area. On admission, a vast range of pathogens causing this severe community-acquired pneumonia was considered ; in Brazil, the most common pathogens of (severe) community-acquired pneumonia include Streptococcus pneumoniae, Legionella spp., Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Gram-negative rods, and respiratory viruses [26][27][28]. Based on the low prevalence of penicillin-resistant pneumococci in Brazil [28], the guidelines for the treatment of communityacquired pneumonia as provided by the Brazilian Society for Infectious Diseases recommend third-or fourth-generation cephalosporins plus a macrolide intravenously as first-choice treatment for severe pneumonia [26].…”